Completed PHASE2 INTERVENTIONAL 1-arm NCT00230542

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Phase II Study of Carboplatin and Pemetrexed in Patients With Recurrent Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor: Brigham and Women's Hospital

Conditions Fallopian Tube Cancer Ovarian Cancer Peritoneal Cancer

Interventions Carboplatin Pemetrexed

Updated 7 times since 2017 Last updated: Aug 10, 2018 Started: Sep 30, 2005 Primary completion: Jul 31, 2007 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Fallopian Tube Cancer and Ovarian Cancer, this trial is completed. The trial is conducted by Brigham and Women's Hospital and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Sep 2018 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brigham and Women's Hospital
Dana-Farber Cancer Institute
Massachusetts General Hospital

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States